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Toward a Better Understanding of...

Linkage of Lipid-Lowering, Blood Pressure,
and Antidepressant Medications with
Cognitive and Imaging Based Markers
of Alzheimer’s Pathology
Vineeth Thirunavu
Mentor: Tammie Benzinger
The effect of statins, beta blockers, selective serotonin reuptake inhibitors (SSRIs), and
other drug classes on Alzheimer’s pathology is not well characterized. The objective of
this project was to investigate potential relationships between these drugs and certain
measures reflective of Alzheimer’s pathology. Participants in ongoing studies on aging
and dementia from the Knight Alzheimer Disease Research Center at Washington
University were selected for this analysis. Medication data was self-reported for all
participants, so a string matching algorithm in R was used to correct spellings and classify
drugs into different categories (statins, beta blockers, etc). These participants (~13,000)
have Aβ and tau PET imaging, CSF, structural MRI, and clinical dementia rating (CDR)
measures. APOE4 status (APOE4 allele increases risk of Alzheimer’s disease), gender, and
education levels were controlled for. Basic linear regressions and general linear models
show that statins delay the onset of dementia associated with Alzheimer’s disease, but
there is no evidence to suggest that statins slow the progression of Alzheimer’s pathology
after onset. Additionally, no trend was found between beta blocker usage and Alzheimer’s
onset or progression of pathology. Genotypic analysis to investigate rates of drug usage
between APOE4 carriers and non-APOE4 carriers reveals that proton pump inhibitors
(PPIs) are used at a significantly lower rate among APOE4 carriers (p = 0.00174), and
SSRIs are used at a higher rate among APOE4 carriers (p = 0.08671). This uneven usage
may serve as a basis for further exploration of the relationship between these drugs and
Alzheimer’s disease.
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